Brief: Anika Therapeutics Completes Enrollment Of Phase III Clinical Study For Hyalofast
30/05/2023 22:39
May 30 (Reuters) - Anika Therapeutics Inc ANIK.O :
* ANIKA THERAPEUTICS INC-COMPLETED ENROLLMENT OF PIVOTAL
PHASE III
CLINICAL STUDY FOR HYALOFAST ON PATH TO ACHIEVING FDA APPROVAL
IN US
* ANIKA THERAPEUTICS INC-HYALOFAST HAS BEEN DESIGNATED AS
BREAKTHROUGH DEVICE BY FDA
* ANIKA THERAPEUTICS INC-TO BEGIN FILING MODULAR PMA IN 2024
WITH
FINAL MODULE FILING EXPECTED IN 2025
Source text for Eikon: ID:nGNX12H66t
Further company coverage: ANIK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anika Therapeutics
See all newsAnika Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Anika Therapeutics Q2 revenue rises, lifts 2026 outlook
Anika Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Anika Therapeutics Enters Fifth Amendment To Credit Agreement - SEC Filing
Anika Therapeutics Q1 revenue rises 13%